​On July 26, the closing prices of four stocks dropped by more than 2% relative to the VWAP, and a shift below the VWAP suggests a potential bearish trend.

Syngene International and 4 other stocks close below VWAP

Citi has maintained a sell call on Ramco Cements, raising the target price to Rs 750 from Rs 735. Despite stable EBITDA per ton, Ramco has lost market share by not selling at significantly lower prices. The stock is expected to underperform until the company resolves the conflict between market share and pricing.

Hot stocks: Brokerage view on Ramco Cements, Tech Mahindra, Laurus Labs, Syngene and Cyient

Syngene Q1 Earnings: In-Line Profits Recorded, What's The Growth Outlook Of Company In Future?

'Got Super Modern Laboratories In India': Syngene International MD & CEO

Syngene Q1FY25 Results: Syngene International Limited reports 19% dip in profit, plans to expand biologics manufacturing capacity for growth.

Syngene Q1 Results: Net profit down 19% to ₹75.7 crore

Result Review | How were the Results for Petronet LNG Futures & Syngene Intl ?

Syngene International, the contract research and manufacturing services arm of Biocon, reported 19% year-on-year (YoY) drop in net profit to Rs.76 crore in Q1FY25 led by discovery services revenue taking a hit due to funding constraints at US biotechs.

Syngene Q1 Results: Net profit drops 19% to Rs 76 crore

Syngene International consolidated net profit declines 18.95% in the June 2024 quarter

Upcoming results:Larsen and Turbo, Axis Bank, Aditya Birla Sun Life AMC, Bajaj Finserv, Bajaj Holdings, Bikaji Foods, CMS Info System, Craftsman Automation, DCB Bank, Federal Bank, Go Fashion, HFCL, Indian Energy Exchange, IGL, Jindal Steel and Power, JK Paper, KPIT Tech, Karnataka Bank, Mahindra Lifespace Developers, MAS Financial Services, Oracle Financial Services, Petronet, PG ELectroplast, Hitachi Energy, Ramkrishna Forgings, SBI Life Insurance, Sona BLW Precision Forging amd Syngene International.

Stock Alert: Bajaj Finance, Hindustan Unilever, Torrent Pharma, Schaeffler India, ICICI Securities,

Syngene International’s Q4 revenue was down 7.8% to Rs 916.9 crore as against an estimate of Rs 1,024 crore.

Syngene International Q4 Results: Profit Up 5.5% At Rs 188.6 Crore, Revenue Falls

It has revised its target prices for Syngene International Limited and Neuland Laboratories Ltd.

Goldman Sachs Advises Shareholders To Sell And Buy Their Stakes In These Firms - News18

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Syngene International Limited is a contract research company. It is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies.